Michael Thomas Serzan
Harvard University · 50 works · 262 citations · h-index 9
Top works
- Takotsubo Cardiomyopathy Associated With Checkpoint Inhibitor Therapy
- Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis
- The Risk of Opportunistic Infections and the Role of Antibiotic Prophylaxis in Patients on Checkpoint Inhibitors Requiring Steroids
- Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy
- Current and emerging therapies for first line treatment of metastatic clear cell renal cell carcinoma
- Delayed toxicities with anti-PD-1 and anti-PDL-1 immune checkpoint inhibitors (ICIs).
- Clinical Outcomes of Immune Checkpoint Inhibitors in Unique Cohorts Underrepresented in Clinical Trials
- Management of Renal Cell Carcinoma
- The impact of immunosuppressive agents on immune checkpoint inhibitor efficacy in patients with advanced melanoma: A real‐world, multicenter, retrospective study
- Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Living Guideline, Version 2026.1
- Drugs in development for small cell lung cancer
- Real-world outcomes of underrepresented patient populations treated with immune checkpoint inhibitors (ICIs): African American descent, poor ECOG performance status, and chronic viral infections.
- Adjuvant therapy for patients with renal cell carcinoma following surgery: a focus on pembrolizumab
- Wellness Councils Build Capacity for School-Based Obesity Prevention in Harlem and Washington Heights, New York City
- First-Line Treatment for Intermediate and Poor Risk Advanced or Metastatic Clear Cell Renal Cell Carcinoma
- P2.07-050 Impact of Steroid Use for Immune Related Adverse Events on Outcomes in Non-Small Cell Lung Cancer (NSCLC) Treated with Checkpoint Inhibitors
- Clinical outcome of immune related hepatitis (IrHep) in patients with advanced melanoma (AM) treated with single agent or combination immune checkpoint inhibitors (ICIs)
- Correction: Zhang et al. Association between Body Mass Index and Immune-Related Adverse Events (irAEs) among Advanced-Stage Cancer Patients Receiving Immune Checkpoint Inhibitors: A Pan-Cancer Analysis. Cancers 2021, 13, 6109
- P21.07 Immune-Related Adverse Events with Durvalumab Consolidation in a Real-World Cohort of Patients with Non–Small Cell Lung Cancer (NSCLC)
- P-056 Outcome of maintenance therapy in patients who achieved NED after liver resection for mCRC